Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, provides an update on the Phase III ENERGIZE trial (NCT04770779) investigating the safety and efficacy of mitapivat in patients with non-transfusion-dependent (NTD) alpha- or beta-thalassemia. The results are positive, with the study meeting its primary and secondary endpoints. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
